Nexentis Technologies Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. PROPERTIES
We lease office space in Miami, Florida. We renewed our lease in December 2025 for one year until December 2026, with an option to renew it for an additional one-year term. Our current monthly rent payment is $703.
Additionally, laboratory and office facilities used by our subsidiary MitoCareX are located at the Daren Labs facility in Ness Ziona, Israel. Pursuant to a services agreement extended in October 2025, MitoCareX leases laboratory and office space consisting of several laboratory and office rooms. The agreement is in effect through October 31, 2026. The current monthly payment for the use of these facilities is approximately NIS 33,250 (approximately $10,400) plus VAT.
Our former commercialization and manufacturing operations, which are classified as discontinued operations, were conducted at Neve Yarak (Israel) where we lease approximately 230 square meters of space to run our trials. The lease expired on August 31, 2025, and was extended for an additional one-year period, until August 31, 2026. Our current monthly rent payment is NIS 7,000 (approximately $2,200).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.